- Home
- AMSF vs LBRX Comparison
AMSF vs LBRX Comparison
Compare AMSF & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | LBRX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.9M | 602.6M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMSF | LBRX |
|---|---|---|
| Price | $33.74 | $24.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $55.00 | $49.00 |
| AVG Volume (30 Days) | 128.7K | ★ 181.8K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $309,043,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | $19.21 | ★ N/A |
| Revenue Growth | ★ 0.71 | N/A |
| 52 Week Low | $36.23 | $13.40 |
| 52 Week High | $53.27 | $25.60 |
Technical Indicators
Market Signals| Indicator | AMSF | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 24.35 | 56.55 |
| Support Level | N/A | $22.48 |
| Resistance Level | $39.59 | $24.70 |
| Average True Range (ATR) | 1.12 | 1.21 |
| MACD | -0.35 | -0.00 |
| Stochastic Oscillator | 4.34 | 58.85 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.